Health Care [ 4/12 ] | Pharmaceuticals [ 26/74 ]
NASDAQ | Common Stock
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 4, 25 | -0.03 Increased by +70.00% | -0.02 Decreased by -50.00% |
| Nov 8, 24 | -0.11 Decreased by -22.22% | -0.09 Decreased by -22.22% |
| Aug 8, 24 | -0.10 Increased by +28.57% | -0.11 Increased by +9.09% |
| May 9, 24 | -0.14 Decreased by -16.67% | -0.12 Decreased by -16.67% |
| Mar 6, 24 | -0.10 Increased by 0.00% | -0.10 |
| Nov 9, 23 | -0.09 Increased by +43.75% | -0.12 Increased by +25.00% |
| Aug 8, 23 | -0.14 Increased by +26.32% | -0.13 Decreased by -7.69% |
| May 9, 23 | -0.12 Increased by +52.00% | -0.17 Increased by +29.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 60.10 M Increased by +35.39% | -5.11 M Increased by +61.81% | Decreased by -8.51% Increased by +71.80% |
| Sep 30, 24 | 54.27 M Increased by +12.31% | -15.74 M Decreased by -29.12% | Decreased by -29.00% Decreased by -14.96% |
| Jun 30, 24 | 48.06 M Increased by +26.46% | -15.01 M Increased by +24.38% | Decreased by -31.22% Increased by +40.20% |
| Mar 31, 24 | 40.64 M Increased by +22.42% | -18.98 M Decreased by -12.75% | Decreased by -46.71% Increased by +7.90% |
| Dec 31, 23 | 44.39 M Increased by +33.93% | -13.39 M Decreased by -3.56% | Decreased by -30.16% Increased by +22.68% |
| Sep 30, 23 | 48.32 M Increased by +62.56% | -12.19 M Increased by +44.17% | Decreased by -25.23% Increased by +65.65% |
| Jun 30, 23 | 38.01 M Increased by +50.19% | -19.84 M Increased by +24.22% | Decreased by -52.20% Increased by +49.55% |
| Mar 31, 23 | 33.20 M Increased by +50.39% | -16.83 M Increased by +50.07% | Decreased by -50.71% Increased by +66.80% |